A single‐institution pre–post comparison of subcutaneous immunoglobulin replacement therapy in allogeneic haematopoietic cell transplantation recipients

Abstract

SummaryImmunoglobulin replacement therapy (IgRT) reduces the risk of infection in hypogammaglobulinaemia secondary to chronic lymphocytic leukaemia and multiple myeloma. However, the benefit of IgRT, especially subcutaneous IgRT (ScIgRT), has not been assessed in hypogammaglobulinaemia after allogeneic haematopoietic cell transplantation (allo‐HCT). We performed a pre–post comparison of the clinical impact of ScIgRT after allo‐HCT in a retrospective analysis of 209 patients who underwent allogeneic HCT at our institution from 2011 to 2019. Since ScIgRT became available at our institution in April 2017, we categorized patients treated from January 2011 to March 2017 as the Pre‐ScIgRT group (n = 118) and those treated from April 2017 to December 2019 as the Post‐ScIgRT group (n = 91). The 2‐year overall survival rate was 65% in the Pre‐ScIgRT group and 81% in the Post‐ScIgRT group (p = 0.02). The cumulative incidence (CI) of non‐relapse mortality at 2 years was 18% and 7% (p = 0.02). There were 78 infectious events in 44 patients in the Pre‐ScIgRT group and 28 such events in 19 patients in the Post‐ScIgRT group. The CI of the documented infection during the observation period was between 38% and 21% (p = 0.01). Our study suggests that ScIgRT may reduce infection rates and improve prognosis after allo‐HCT.